Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

HARDBACK price:$54.95 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources Display this book on your site! Related Titles Environmental Tobacco Smoke:Measuring Exposures and Assessing Health Effects Growing Up Tobacco Free:Preventing Nicotine Addiction in Children and Youths Other Related Titles Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction (2001) Institute of Medicine (IOM) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix A: Presentations and Submissions." Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: The National Academies Press, 2001. Please select a format: Page 581   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendixes Page 581 Front Matter (R1-R20) Executive Summary (1-18) 1 Introduction (19-37) 2 Principles of Harm Reduction (38-59) 3 Historical Perspective and Lessons Learned (60-81) 4 Products for Tobacco Exposure Reduction (82-139) 5 The Scientific Basis for Pres Assessment (140-179) 6 Surveillance for the Health and Behavioral Consequences of Exposure Reduction (180-200) 7 Implementation of a Science-Based Policy of Harm Reduction (201-230) 8 Principal Conclusions (231-240) 9 Nicotine Pharmacology (241-282) 10 Tobacco Smoke and Toxicology (283-308) 11 Exposure and Biomarker Assessment in Humans (309-366) 12 Cancer (367-469) 13 Cardiovascular Disease (470-499) 14 Nonneoplastic Respiratory Diseases (500-542) 15 Reproductive and Developmental Effects (543-559) 16 Other Health Effects (560-580) Appendix A: Presentations and Submissions (581-585) Appendix B: Committee Biographical Sketches (586-592) Appendix C: Time Line of Tobacco Events (593-606) Index (607-636)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 581
Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction Appendixes

OCR for page 582
Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction This page in the original is blank.

OCR for page 583
Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction A Presentations and Submissions The committee would like to thank the following people who shared their expertise. PRESENTATIONS December 15, 1999, Washington, D.C. Presentation of the Charge to the Institute of Medicine Committee Mitch Zeller, Food and Drug Administration (current affiliation, American Legacy Foundation Bern Schwetz, Food and Drug Administration March 2, 2000, Washington, D.C. Harm Reduction and Lessons Learned: Historical Perspective and Policy Advice John Slade, University of Medicine and Dentistry at New Jersey School of Public Health Harm Reduction and Lessons Learned: Low Tar and Nicotine Story Don Shopland, National Cancer Institute Tobacco Toxicology Review: Emphasis on Carcinogenesis Steve Hecht, University of Minnesota Exposure Assays David Ashley, Centers for Disease Control and Prevention Nicotine Pharmacology and Toxicology Neal Benowitz, University of California, San Francisco

OCR for page 584
Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction April 25, 2000, Washington, D.C. Risk Perception and Decision Making Paul Slovic, Decision Research, University of Oregon Epidemiology of Low-Tar Cigarettes David Burns, University of California, San Diego Clinical Trial Design Considerations Jack Henningfield, Pinney Associates, Johns Hopkins School of Medicine Janine Pillitteri, Pinney Associates John Hughes, University of Vermont Clinical Indicators of Chronic Obstructive Pulmonary Disease Steve Rennard, University of Nebraska Physical and Chemical Characteristics of Tobacco Smoke Robert Phalen, University of California, Irvine State of Massachusetts Regulation of Tobacco Products Gregory Connolly, Massachusetts Department of Public Health Michael Borgerding, R.J. Reynolds Tobacco Company CONTRIBUTIONS Thoughtful contributions were also provided by the following: Industry Representatives Brown and Williamson Tobacco Company Scott Appleton Sharon Boyse Rufus Honeycutt Tilford Riehl Lorillard Tobacco Company Christopher Coggins and colleagues Chuck Gaworski J.Dan Heck Philip Morris Tobacco Company Richard A.Carchman Bruce D.Davies Hans-Juergen Haussmann Robin D.Kinser Donald E.Leyden George J.Patskan Richard P.Solana Anthony R.Ticker

OCR for page 585
Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction R.J. Reynolds Tobacco Company Michael Borgerding J.Donald deBethizy David Doolittle David Iauco Arnold T.Mosberg Seth Moskowitz John H.Robinson Robert L.Suber James E.Swauger Star Scientific, Inc. Scott D.Ballin Jerome H.Jaffe Paul L.Perito GlaxoWellcome Pharmacutical Brenda Jamerson Pharmacia Corporation Mikael Franzon Vibeke Kronborg Smith Kline Beecham Individuals Gregory Dalack, VA Ann Arbor Healthcare System Karl Fagerstrom, Fagerstrom Consulting Nigel Gray, European Institute of Oncology Jack Henningfield, Pinney Associates Thomas Houston, American Medical Association John Hughes, University of Vermont Anne Kirchner, Food and Drug Administration Robert Nilsson, National Chemicals Inspectorate, Sweden Brad Radu, University of Alabama Elsy-Britt Schildt, University Hospital, Sweden Saul Shiffman, University of Pittsburgh and Pinney Associates John Slade, University of Medicine and Dentistry at New Jersey School of Public Health Steven Stellman, American Health Foundation David Sweanor, Smoking and Health Action Foundation, Canada Puzant Torigian Dennis Ole Wik Judy Wilkenfeld, Campaign for Tobacco Free Kids Richard Windsor, University of Alabama

Representative terms from entire chapter:

pinney associates